Cryosite Limited (AU:CTE)
ASX:CTE
Want to see AU:CTE full AI Analyst Report?
Top Page
Cryosite Limited
(Sydney:CTE)
Select Model
Select Model
Rating:60Neutral
Price Target:
AU$1.00
▲(0.00% Upside)
Action:ReiteratedDate:02/10/26
The score is driven mainly by solid financial performance (strong margins and revenue growth) but is held back by weaker cash-flow trends and balance-sheet reliance on debt. Technically, momentum is strong but extremely overbought (very high RSI), increasing near-term risk. Valuation is a drag due to a relatively high P/E and no dividend yield provided.
Positive Factors
Consistent Revenue Growth
Near-10% annual revenue growth indicates expanding demand and successful commercial execution across the core diagnostics and research business. That pace supports durable top-line momentum, enabling reinvestment in product capabilities and scaling fixed-cost leverage over the next several quarters.
Negative Factors
Elevated Leverage / Low Equity Ratio
A near-1.0 D/E and low equity ratio indicate meaningful reliance on debt to fund operations and growth. Over a multi-month horizon this raises refinancing and interest rate exposure, constrains strategic flexibility, and amplifies downside risk if revenue or margins deteriorate unexpectedly.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent Revenue Growth
Near-10% annual revenue growth indicates expanding demand and successful commercial execution across the core diagnostics and research business. That pace supports durable top-line momentum, enabling reinvestment in product capabilities and scaling fixed-cost leverage over the next several quarters.
Read all positive factors
Cryosite Limited (CTE) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$56.13M
Dividend YieldN/A
Average Volume (3M)1.97K
Price to Earnings (P/E)10.7
Beta (1Y)-0.30
Revenue Growth22.56%
EPS Growth19.47%
CountryAU
Employees25
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.04
Shares Outstanding48,809,563
10 Day Avg. Volume3,337
30 Day Avg. Volume1,969
Financial Highlights & Ratios
PEG Ratio8.08
Price to Book (P/B)15.22
Price to Sales (P/S)2.58
P/FCF Ratio24.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cryosite Limited Business Overview & Revenue Model
Company Description
Cryosite Limited offers outsourced clinical trials logistic services in Australia. It operates through two segments, Clinical Trials and Biological Services Logistics, and Cord Blood and Tissues Storage. The Clinical Trials and Biological Services...
Cryosite Limited Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
65
Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.75M | 14.12M | 12.61M | 11.94M | 11.76M | 10.02M |
| Gross Profit | 9.29M | 8.89M | 7.99M | 6.48M | 6.27M | 5.31M |
| EBITDA | 3.74M | 3.41M | 3.04M | 2.30M | 2.40M | 1.65M |
| Net Income | 2.18M | 1.88M | 1.84M | 1.41M | 1.36M | 652.57K |
Balance Sheet | ||||||
| Total Assets | 26.55M | 19.46M | 19.71M | 22.65M | 21.50M | 21.99M |
| Cash, Cash Equivalents and Short-Term Investments | 2.54M | 5.06M | 4.70M | 5.73M | 5.34M | 3.88M |
| Total Debt | 8.82M | 2.27M | 2.44M | 2.61M | 849.76K | 1.07M |
| Total Liabilities | 22.94M | 17.07M | 18.26M | 19.86M | 19.64M | 21.17M |
| Stockholders Equity | 3.61M | 2.39M | 1.45M | 2.78M | 1.86M | 819.23K |
Cash Flow | ||||||
| Free Cash Flow | -1.70M | 1.48M | 2.44M | 1.19M | 1.63M | 80.07K |
| Operating Cash Flow | 2.23M | 2.06M | 2.90M | 1.49M | 2.49M | 476.96K |
| Investing Cash Flow | -3.84M | -420.00K | 727.00K | -1.33M | -863.19K | -396.89K |
| Financing Cash Flow | -332.00K | -1.29M | -3.50M | -768.00K | -148.99K | -260.78K |
Cryosite Limited Technical Analysis
Negative
1.00
Price Trends
1.17
Negative
1.11
Negative
0.99
Positive
Market Momentum
-0.02
Positive
19.48
Positive
93.17
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CTE, the sentiment is Negative. The current price of 1 is below the 20-day moving average (MA) of 1.12, below the 50-day MA of 1.17, and above the 200-day MA of 0.99, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 19.48 is Positive, neither overbought nor oversold. The STOCH value of 93.17 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CTE.
Cryosite Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | AU$56.13M | 10.72 | 72.82% | ― | 22.56% | 19.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$46.28M | -1.06 | -63.04% | ― | -11.81% | -21.45% | |
44 Neutral | AU$157.06M | -7.39 | -164.12% | ― | -14.85% | -41.04% | |
42 Neutral | AU$30.60M | -2.45 | -164.22% | ― | ― | 26.04% | |
41 Neutral | AU$50.97M | -4.75 | -476.27% | ― | ― | -142.39% | |
38 Underperform | AU$45.75M | -3.02 | -37.14% | ― | 4.66% | 12.39% |
* Healthcare Sector Average
AU:CTE
Cryosite Limited
1.15
0.37
47.44%
AU:BDX
BCAL Diagnostics Limited
0.08
<0.01
3.75%
AU:RHY
Rhythm Biosciences Ltd.
0.14
0.08
122.22%
AU:LDX
Lumos Diagnostics Holdings Ltd.
0.17
0.14
466.67%
AU:IIQ
Inoviq Ltd
0.33
-0.05
-14.47%
AU:MAP
Microba Life Sciences Limited
0.08
-0.11
-58.92%
Cryosite Limited Corporate Events
Cryosite issues 666,666 unquoted options under employee incentive scheme
Mar 18, 2026
Cryosite Limited has issued 666,666 unquoted options under its employee incentive scheme, with various exercise prices and expiry dates, as notified in an Appendix 3G filing to the ASX dated 18 March 2026. The move underscores the company’s ...
Cryosite posts record half-year results and doubles capacity with new facility
Feb 26, 2026
Cryosite reported record first-half FY26 revenue of $8.3 million, up 25% year on year, with EBITDA rising 33% to $2.0 million as margins expanded and operating leverage improved. Growth was broad-based across ambient, cold and frozen, and ultra-fr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.